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http://dx.doi.org/10.1016/j.jmii.2013Background: Adherence to treatment remains a key issue for tuberculosis (TB) and human im-
munodeficiency virus (HIV) programs. The study objective was to identify potential determi-
nants of medication adherence (MA) among patients with TB, HIV, or both.
Methods: In this cross-sectional study, adult patients attending TB or HIV clinics were recruited
in two main regions (Centre and Hauts-Bassins) of Burkina Faso from August to October 2010.
Questionnaires were collected and simple and multiple step-wise linear regression models
were used to identify predictors of MA.
Results: In total, 1043 patients (309 with TB, 553 with HIV, and 181 coinfected with both)
participated in this study. For patients with TB, adjusted predictors of good MA were no alcohol
use, ever been lost to follow-up, and awareness of disease transmission. For patients with HIV,nfectious Disease and Cancer Research, Kaohsiung Medical University, No. 100 Shih-Chuan 1st Road,
w (Y.-M.A. Chen).
an Society of Microbiology. Published by Elsevier Taiwan LLC. All rights reserved.
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Medication adherence predictors for TB and HIV 223adjusted predictors of good MA were less stigma, good knowledge about TB transmission, and
awareness of disease transmission. For patients with dual infection, adjusted predictors of
good MA was good attitude. Furthermore, adjusted predictors of poor MA for patients with
TB or with dual infection were poor financial access to care and high number of persons
sleeping in the household, respectively.
Conclusion: This study provides information on MA in patients infected with TB, HIV, and those
coinfectedwith TB andHIV. TB andHIV programs have to consider the environment of the patient
and its characteristics, including stigma, attitude, status of loss to follow-up, TB knowledge,
financial access to care, alcohol use, awareness of disease transmission, and number of persons
sleeping in the household. These identified factors in this study need to be taken into account for
a specific patient profile and during sensitization, project planning, and research stages.
Copyright ª 2013, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
The World Health Organization (WHO) has stated that
tuberculosis (TB) and human immunodeficiency virus (HIV)
infections will be among the top 20 causes of death up to
2030.1 Both are chronic infectious diseases that mainly
affect the most disadvantaged populations, involve com-
plex treatment regimens with potentially severe side ef-
fects, and are frequently associated with non-adherence to
treatment, which may result in drug resistance.2,3
According to Bangsberg et al, adherent patients have a
longer period of successful treatment and also have lower
mortality rates than patients who are less adherent in urban
settings of San Francisco.4 Access to anti-TB treatment and to
antiretroviral (ARV) medication has become more widely
available. For Corless et al, the question remains as to how to
maintainhighadherencewith respect toARV treatment in the
context of lack of food and other basic necessities in Durban,
South Africa5; in the context where interrupted treatment
may reduce treatment efficacy and cause drug resistance, it
can result in increased morbidity and mortality as well as
additional infections.6 It is known that adherence rates to
long-term medication in high income countries have been
estimated to be only 50%, whereas adherence in developing
countries seems to be even lower.2 Therefore, adherence of
TB and HIV/AIDS patients to treatment remains a challenge.
An important difference in medication adherence between
TB and HIV patients is that TB patients only need to take 6e9
months of medication and HIV patients need lifelong treat-
ment. Additionally, some factors have not been considered in
previous studies: ever been lost to follow-up, duration of
residence, number of persons sleeping in the household, first
choice for consultation for the disease, awareness of disease
transmission, and psychosocial consequences of the disease.
Using a large range of variables, the present study aims to
identify potential determinants of medication adherence
among patients with TB, HIV, and patients coinfectedwith TB
and HIV in a developing country, Burkina Faso.
Methods
Study type and setting
This cross-sectional study uses a survey conducted in
health centers and non-governmental organizations (NGOs)located in the Centre and Hauts-Bassins regions of Burkina
Faso. These two regions harbor approximately 40% of the
TB cases nationwide, have the highest HIV prevalence, and
have the largest number of NGOs providing ARV treatment
in the country.
In the Centre region, TB patients were identified from
data provided by the National TB Diagnosis, Treatment and
Research Centre, and five Health Districts (HDs), namely
Boulmiougou, Baskuy, Sig-Noghin, Bogodogo, and Nongr-
Massom. In the Hauts-Bassins region, TB patients were
identified from data provided by the Regional TB Diagnosis
and Treatment Centre (TDTC), Souro Sanou National
Teaching Hospital (NTH), and six HDs, namely Orodara, Do,
Dafra, Lena, Hounde´, and Karangasso-Vigue´. In total, 309
incident TB cases and 52 prevalent TB cases participated in
this study.
HIV patients were identified from data provided by
various NGOs and HDs, which were the same as those for TB
patients. The NGOs were the Association-Espoir-Vie (AES)
and Responsabilite´-Espoir-Vie-Solidarite´ (REVSþ) from Bobo
Dioulasso in the Hauts-Bassins region; and the Association
des Jeunes pour la Promotion des Orphelins (AJPO) from
Ouagadougou in the Centre region.
Sample size calculation
Sample size was calculated using the online sample size
calculation provided by RASOFT.7 A common margin of error
of 5% was used. Thus, a confidence level of 95% was chosen,
with a response distribution of 50%, a power equal to 80%,
and assuming a normal distribution. With the knowledge
that the total number of TB cases for both regions was 1832
in 2008,8,9 the minimal TB sample size expected was 316
cases for the two regions. In addition, in terms of HIV
sample size, the normal rule of having one case for at least
two controls was applied; thus, at least 600 HIV cases were
needed.
Study planning, research approval, and
recruitment of patients
The study was conducted from 1 August to 8 October, 2010
after advice and guidance was obtained from the National
Yang-Ming University of Taipei (Taiwan) and from the Na-
tional TB program of Burkina Faso, together with an expert
224 Z.C. Me´da et al.opinion from the West African Health Organization. The
study was approved by the Research Ethics Committee of
Burkina Faso and the Ministry of Health in July 2010. With
these approvals, we obtained administrative support that
facilitated carrying out the study in the various health re-
gions and districts within the Centre and Hauts-Bassins
regions.
This study used a consecutive patient method. The in-
clusion criteria were filled when the patient was a confirmed
TB case from a TB clinic and was undergoing anti-TB treat-
ment. Similar criteria were used for HIV cases from AIDS
clinics under highly active antiretroviral therapy (HAART). In
addition, the patient was required to be 15 years and older,
and living in the study setting. Both sexes were included.
Formative research and data collection
After obtaining informed consent from each patient, a
face-to-face interview was conducted using a semi-
structured questionnaire consisting of two parts. The first
part recorded the individual’s clinical information and
comorbidities (10e15 minutes) and was completed during
the interview. The remaining section of the questionnaire
needed 25e30 minutes to be completed.
The independent variables were sociodemographic and
economic status (age, sex, area, region, education level,
religion, profession, monthly income, means of trans-
portation, adapted self-esteem (eight-item scale, with
Cronbach’s a Z 0.873),10 adapted quality of life from the
WHO quality of life (feelings about life, capability, and
expectations for the future, with an eight-item scale,
Cronbach’s a Z 0.726),11 adapted knowledge index about
TB,12 adapted attitude index,12 adapted perception index
(discrimination and isolation),13 awareness of disease
transmission (three-item scale, Cronbach’s a Z 0.783).
Medication adherence was measured using the Morisky
scale (eight-item scale, Cronbach’s a Z 0.711).14 It is aFigure 1. Participants andvalidated and qualified scale which is an indirect method for
evaluating medication with behavior using a self-report and
patient behavior in the context of chronic diseases. In this
regard, we minimized the effect linked to the duration of
treatment in different patients at different stages and avoi-
ded the effect of insufficientmanaging bymedical charts.We
referred only to anti-TB and ARV treatments according to the
context in Burkina Faso: the drugs for prevention were not
systematically used. The sum of medication adherence index
ranged from zero (lowest) to eight (highest). Predictors of
good adherence were defined as those that were positively
correlated with medication adherence, whereas poor pre-
dictors were defined as those thatwere negatively correlated
with medication adherence.
In addition to collecting psychosocial and behavioral
information from patients, data were also collected on
present or past clinical information (CD4 cell count, dia-
betes, cardiovascular disease, arterial hypertension, and
pulmonary asthma), health system-related factors
(financial and geographical access, work force perceived
by patients, waiting time of consultation), first place of
consultation (when sick, for present disease, and when
having cough), duration of residence, past history of TB,
having ever been lost to follow-up, comorbidities [smok-
ing, alcoholism, prisoner status, knowledge of viral hep-
atitis B and C, sexually transmitted infections (STIs), and
injection drug use (IDU)], psychosocial consequences of
the disease, type of alimentation, and sexual orientation.
Before conducting the final survey, the questionnaire
underwent pretesting in order to reduce bias and to
better control the time needed for completing the
questionnaire.
HIV testing and TB confirmation
HIV status and TB status were confirmed from the medical
and biological records of each patient. In TB patients, TBsample characteristics.
Table 1 Univariate and multivariate analyses of potential factors that predict medication adherence
Influential factors Subgroups Frequency Adherence
score
mean  SD
t test Univariate analysis Multivariate analysis
Test
value
p b Lower
bound
Upper
bound
p b Lower
bound
Upper
bound
p
Status of patient TB and HIV 862 6.3  1.6 2.307 0.021 0.307 0.046 0.568 0.021 0.146 0.119 0.411 0.281
Coinfected 181 6.0  1.8
Alcohol No 777 6.4  1.5 5.221 <0.001 0.642 0.418 0.866 <0.001 0.366 0.144 0.589 0.001
Yes 266 5.8  1.8
Illegal drug use Never 967 6.3  1.6 3.225 0.001 0.623 0.244 1.003 0.001 0.455 0.093 0.817 0.014
At least once 76 5.7  1.6
Having ever been lost
to follow-up
Yes 619 6.4  1.6 2.773 0.006 0.288 0.087 0.489 0.005 0.240 0.041 0.438 0.018
No 424 6.1  1.7
First choice for
consultation when sick
Clinics 975 6.3  1.7 5.128 <0.001 0.587 0.872 0.302 <0.001 0.133 0.435 0.169 0.387
Healers 68 5.0  1.8
First choice for
consultation about
present disease
Healers 228 5.8  1.8 4.648 <0.001 0.602 0.839 0.365 <0.001 0.272 0.527 0.017 0.036
Clinics 815 6.4  1.6
First choice for consultation
when having cough
Clinics 822 6.4  1.6 2.788 0.006 0.365 0.124 0.607 0.003 0.200 0.464 0.065 0.139
Healers 221 6.0  1.8
Waiting time perceived
by patients
Longer 290 6.1  1.7 2.302 0.022 0.259 0.479 0.038 0.022 0.022 0.238 0.193 0.839
Acceptable 753 6.3  1.6
Number of persons sleeping
in the household
1043 0.030 0.051 0.010 0.004 0.023 0.043 0.004 0.018
Attitude 1043 0.058 0.033 0.082 <0.001 0.031 0.001 0.062 0.057
Financial access to health
care index
1043 0.125 0.027 0.223 0.013 0.248 0.120 0.377 <0.001
Work force perceived by
patient index
1043 0.228 0.127 0.328 <0.001 0.101 0.001 0.201 0.050
Self-esteem index 1043 0.051 0.032 0.069 <0.001 0.015 0.009 0.039 0.213
Stigma index 1043 0.124 0.087 0.161 <0.001 0.097 0.044 0.150 <0.001
Discrimination and isolation index 1043 0.149 0.097 0.201 <0.001 0.028 0.031 0.088 0.347
Awareness of disease transmission index 1043 0.095 0.069 0.121 <0.001 0.057 0.030 0.083 <0.001
Knowledge about TB transmission index 1043 0.033 0.010 0.057 0.005 0.013 0.018 0.044 0.410
SD Z standard deviation.
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226 Z.C. Me´da et al.smear result was considered positive when at least two
sputum samples of the patient were examined and the
germ of the TB disease was detected by light microscopy
after Ziehl-Neelsen staining. In HIV patients, a HIV test was
positive when antibodies were detected by an initial test
based on the ELISA method, and then confirmed by a second
test using the Western blot procedure.
Data analysis
Data were entered into EPIDATA (3.0 Software, EpiData
Association, Odense, Denmark) and analyzed by the SPSS PC
statistical package, version 17.0 (SPSS Inc., Chicago, IL,
USA). The cut-off point for continuous variables was the
median. The level of significance was 0.05. A comparison of
the variables between patients with TB, HIV, and both was
carried out using the Chi-square test for categorical data
and a two-sample t test or F test for continuous data.Table 2 Univariate and multivariate analyses of potential facto
Subgroups Frequency Adherence
score
mean  SD b
Alcohol use No 216 6.6  1.4 0.98
Yes 93 5.6  1.8
Illegal drug use Never 271 6.4  1.6 0.82
At least
once
38 5.6  1.6
Having ever been
lost to follow-up
Yes 236 6.6  1.5 1.25
No 73 5.4  1.6
First choice for
consultation
when sick
Clinics 283 6.4  1.6 0.44
Healers 26 5.3  1.8
First choice for
consultation about
present disease
Clinics 214 6.5  1.4 0.62
Healers 95 5.9  1.8
First choice for
consultation when
having cough
Clinics 262 6.3  1.6 0.15
Healers 47 6.2  1.6
Waiting time
perceived by
patients
Longer 82 6.0  1.6 0.43
Acceptable 227 6.4  1.6
Number of persons
sleeping in the
household
309 0.02
Attitude 309 0.19
Financial access to
health care index
309 0.37
Work force perceived
by patient index
309 0.22
Self-esteem index 309 0.05
Stigma index 309 0.15
Discrimination and
isolation index
309 0.13
Awareness of disease
transmission index
309 0.06
SD Z standard deviation.Simple and multiple stepwise linear regression models were
then used to identify predictors of the medication adher-
ence index. Only significant predictor factors of medication
adherence at the univariate analysis were entered into the
model for multivariate analysis.
Results
Participants and sample characteristics
There were 1290 patients who met the inclusion criteria
during data collection (Fig. 1). After eligibility and
enrollment, the sample size under study was reduced to
1043 participants out of which 605 patients were from HIV
clinics (from public sector and NGOs, and 52 were coin-
fected with TB and HIV) and 438 from TB clinics (all from
public sector, and 129 were coinfected with TB and HIV).
The non-eligible cases were those who refused to respondrs that predict medication adherence for TB patients
Univariate analysis Multivariate analysis
Lower
bound
Upper
bound
p b Lower
bound
Upper
bound
p
7 0.610 1.363 <0.001 0.621 0.258 0.984 0.001
1 0.281 1.361 0.003 0.493 0.010 0.997 0.055
1 0.852 1.651 <0.001 0.986 0.597 1.376 <0.001
6 0.863 0.030 0.036 0.030 0.381 0.441 0.886
7 1.011 0.244 0.001 0.370 0.770 0.031 0.070
0 0.351 0.651 0.556
4 0.838 0.029 0.036 0.062 0.472 0.348 0.767
9 0.069 0.011 0.158
6 0.099 0.294 <0.001 0.054 0.049 0.157 0.307
0 0.621 0.119 0.004 0.387 0.620 0.154 0.001
9 0.042 0.416 0.016 0.010 0.187 0.207 0.921
4 0.026 0.082 <0.001 0.010 0.023 0.043 0.555
7 0.087 0.227 <0.001 0.070 0.012 0.152 0.095
7 0.052 0.222 0.002 0.020 0.077 0.116 0.691
3 0.008 0.118 0.024 0.058 0.006 0.110 0.030
Medication adherence predictors for TB and HIV 227to the questions and the questionnaire (n Z 69), HIV pa-
tients who were not under ARV treatment (n Z 20), and
those who responded but provided incomplete information
(n Z 58). This final sample of 1043 patients consisted of
309 TB patients, 553 HIV/AIDS cases, and 181 patients
coinfected with TB and HIV. All patients were heterosexual
and ate mixed food.Factors that differ among TB infected, HIV
infected, and TB/HIV coinfected patients
There were no differences among patients with TB, HIV,
and TB/HIV coinfection in alcohol status, waiting time
perceived by patients, patient status (TB infected and
HIV infected versus coinfected with TB and HIV), everTable 3 Univariate and multivariate analyses of potential facto
Subgroups Frequency Adherence
score
mean  SD b
Alcohol No 450 6.4  1.6 0.24
Yes 103 6.1  1.7
Illegal drug use Never 526 6.4  1.6 0.54
At least
once
27 5.8  1.6
Having ever been
lost to follow-up
Yes 265 6.3  1.6 0.07
No 288 6.4  1.6
First choice for
consultation
when sick
Clinics 543 6.4  1.6 0.15
Healers 10 6.3  1.2
First choice for
consultation
about present
disease
Clinics 491 6.4  1.6 0.28
Healers 62 6.1  1.6
First choice for
consultation
when having cough
Clinics 435 6.4  1.6 0.22
Healers 118 6.2  1.7
Waiting time
perceived by
patients
Longer 147 6.2  1.5 0.16
Acceptable 406 6.4  1.6
Number of persons
sleeping in the
household
553 0.01
Attitude 553 0.05
Financial access to
health care index
553 0.19
Work force perceived
by patient index
553 0.09
Self-esteem index 553 0.09
Stigma index 553 0.20
Discrimination and
isolation index
553 0.13
Awareness of disease
transmission index
553 0.10
Knowledge about TB
transmission index
553 0.62
SD Z standard deviation.been lost to follow-up, IDU, place for consultation when
sick and having a cough, and past/present disease history.Predictors of medication adherence index
Univariate analysis predictors for medication adherence
were patient status (TB and HIV infection versus coinfection
with TB and HIV), alcohol status, IDU, ever been lost to
follow-up, first choice for consultation, waiting time
perceived by patients, number of persons sleeping in the
household, attitudes, financial access to care, perceived
work force, self-esteem, stigma, discrimination isolation,
awareness of disease transmission, and knowledge about TB
transmission (Tables 1e3). Sociodemographic variables
were not predictor factors of medication adherence.rs that predict medication adherence for HIV patients
Univariate analysis Multivariate analysis
Lower
bound
Upper
bound
p b Lower
bound
Upper
bound
p
9 0.093 0.590 0.154
5 0.072 1.162 0.083
3 0.339 0.194 0.593
9 0.446 0.763 0.606
3 0.705 0.139 0.188
0 0.105 0.545 0.183
4 0.138 0.465 0.287
1 0.038 0.017 0.461
4 0.022 0.085 0.001 0.024 0.065 0.017 0.247
7 0.410 0.015 0.068
8 0.044 0.240 0.176
1 0.049 0.133 <0.001 0.026 0.022 0.075 0.286
8 0.141 0.275 <0.001 0.116 0.029 0.203 0.009
1 0.050 0.211 0.001 0.050 0.042 0.141 0.287
5 0.073 0.136 <0.001 0.073 0.039 0.108 <0.001
7 0.983 0.272 0.001 0.050 <0.001 0.099 0.048
228 Z.C. Me´da et al.From the pooled data, adjusted predictors of good
medication adherence were no alcohol use, ever been lost
to follow-up, first place consultation for present disease,
financial access to care, perceived work force, less stigma,
and awareness of disease transmission (Tables 1e3).
Furthermore, adjusted predictors of poor medication
adherence were high number of persons sleeping in the
household and consulting healer for present disease. Pa-
tient status was not found to be predictive of medication
taking behavior [b: 0.146 (0.119 to 0.411)].
In TB patients (Table 1), the adjusted predictors of good
medication adherence were no alcohol use, ever been lostTable 4 Univariate and multivariate analyses of potential facto
with TB and HIV infection
Subgroups Frequency Adherence
score
mean 
SD
b
Alcohol No 111 6.3  1.6 0.8
Yes 70 5.5  1.9
Illegal drug use Never 170 6.0  1.8 0.3
At least
once
11 5.7  1.3
Having ever been
lost to follow-up
Yes 63 6.2  1.6 0.3
No 118 5.8  2.0
First choice for
consultation
when sick
Clinics 149 5.9  1.8 1.2
Healers 32 4.5  1.7
First choice for
consultation
about present
disease
Clinics 110 6.4  1.7 0.9
Healers 71 5.4  1.7
First choice for
consultation
when having
cough
Clinics 125 6.3  1.6 0.8
Healers 56 5.5  1.9
Waiting time
perceived by
patients
Longer 61 5.3  1.9 1.0
Acceptable 120 6.4  1.6
Number of persons
sleeping in the
household
181 0.0
Attitude 181 0.2
Financial access
to health care
index
181 0.0
Work force perceived
by patient index
181 0.4
Self-esteem index 181 0.0
Stigma index 181 0.1
Discrimination and
isolation index
181 0.1
Awareness of disease
transmission index
181 0.0
Knowledge about TB
transmission index
181 0.2
SD Z standard deviation.to follow-up, and awareness of disease transmission. Poor
financial access to care was an adjusted predictor of poor
medication adherence.
In HIV/AIDS patients (Table 4), the adjusted predictors
of good medication adherence were fewer stigmata, good
knowledge about TB transmission, and high awareness of
disease transmission.
In patients coinfected with TB and HIV (Table 4), good
attitude was an adjusted predictor of good medication
adherence, whereas high number of persons sleeping in the
household was an adjusted predictor of poor medication
adherence.rs that predict medication adherence for coinfected patients
Univariate analysis Multivariate analysis
Lower
bound
Upper
bound
p b Lower
bound
Upper
bound
p
11 0.293 1.329 0.002 0.273 0.259 0.805 0.313
07 0.776 1.389 0.577
95 0.146 0.935 0.151
19 1.764 0.673 <0.001 0.093 0.667 0.853 0.809
40 1.452 0.429 <0.001 0.428 0.151 1.012 0.157
24 0.277 1.370 0.003 0.240 0.461 0.882 0.401
49 1.574 0.524 <0.001 0.252 0.901 0.397 0.445
84 0.132 0.035 0.001 0.058 0.105 0.012 0.014
07 0.128 0.286 <0.001 0.148 0.047 0.249 0.004
58 0.323 0.207 0.666
95 0.265 0.725 <0.001 0.272 0.003 0.547 0.053
60 0.013 0.107 0.013 0.048 0.107 0.012 0.117
68 0.073 0.263 0.001 0.095 0.024 0.214 0.117
86 0.060 0.312 0.004 0.017 0.132 0.166 0.818
99 0.024 0.174 0.010 0.043 0.032 0.118 0.259
83 0.860 0.294 0.335
Table 5 Description of the variables by patient profile
Variables Profile of patient c2 test or
F test
p
TB, n Z 309 HIV, n Z 553 TB_HIV,
n Z 181
Total,
n Z 1043
Area
dRural 227 (73.5) 149 (26.9) 95 (52.5) 471 (45.2) 177.964 <0.001
dUrban 82 (26.5) 404 (73.1) 86 (47.5) 572 (54.8)
Sex
dFemale 87 (28.2) 405 (73.2) 98 (54.1) 590 (56.6) 164.504 <0.001
dMale 222 (71.8) 148 (26.8) 83 (45.9) 453 (43.4)
Age group
d<36.5 203 (65.7) 280 (50.6) 90 (49.7) 573 (54.9) 20.573 <0.001
d36.5 106 (34.3) 273 (49.4) 91 (50.3) 470 (45.1)
Mean  SD 34.6  13.2 37.5  8.7 36.4  9.6 36.5  10.4 7.573 0.001
Self-esteem (Mean  SD) 30.4  6.3 24.8  3.1 26.3  5.4 26.7  5.3 144.239 <0.001
Quality of life (Mean  SD) 28.8  5.2 23.2  3.8 25.9  5.4 25.4  5.2 150.304 <0.001
Profession
dOthers 238 (77.0) 490 (88.6) 144 (79.6) 872 (83.6) 22.027 <0.001
dPrivateepublic sector 71 (23.0) 63 (11.4) 37 (20.4) 171 (16.4)
Marital status
dWidowed, separated,
and divorced
20 (6.5) 175 (31.6) 32 (17.7) 227 (21.8) 89.648 <0.001
dMonogamous, polygamous,
and cohabiting
209 (67.6) 307 (55.5) 127 (70.2) 643 (61.6)
Single 80 (25.9) 71 (12.8) 22 (12.2) 173 (16.6)
Religion
dOther religion 82 (26.5) 203 (36.7) 73 (40.3) 358 (34.3) 12.604 0.002
dMuslim 227 (73.5) 350 (63.3) 108 (59.7) 685 (65.7)
Ethnic group
dOther ethnic group 123 (39.8) 378 (68.4) 95 (52.5) 596 (57.1) 67.911 <0.001
dMossi 186 (60.2) 175 (31.6) 86 (47.5) 447 (42.9)
Means of transportation
dNone and use 179 (57.9) 364 (65.8) 128 (70.7) 671 (64.3) 9.274 0.010
dScooter, car, and bus use 130 (42.1) 189 (34.2) 53 (29.3) 372 (35.7)
Monthly income
d67 USD 82 (26.5) 232 (42.0) 65 (35.9) 379 (36.3) 20.381 <0.001
d<67 USD 227 (73.5) 321 (58.0) 116 (64.1) 664 (63.7)
Duration of residence
d24 months 105 (34.0) 85 (15.4) 35 (19.3) 225 (21.6) 41.225 <0.001
d>24 months 204 (66.0) 468 (84.6) 146 (80.7) 818 (78.4)
Has ever been lost to follow-up
dYes 236 (76.4) 265 (47.9) 118 (65.2) 619 (59.3) 69.630 <0.001
Financial access to health care
(mean  SD)
2.1  0.7 0.6  0.6 1.6  0.9 1.2  1.0 490.660 <0.001
Geographical access to health care
(mean  SD)
3.2  0.8 2.8  0.9 2.8  0.9 2.9  0.9 15.883 <0.001
Work force perceived by patients
(mean  SD)
4.5  1.0 4.3  0.9 4.1  1.1 4.3  1.0 7.623 0.001
First choice for consultation when sick
dPrivate clinic 31 (10.0) 17 (3.1) 8 (4.4) 56 (5.4) 80.079 <0.001
dPublic clinic 252 (81.6) 526 (95.1) 141 (77.9) 919 (88.1)
dHealers 26 (8.4) 10 (1.8) 32 (17.7) 68 (6.5)
First choice for consultation when
having cough
dHealers 47 (15.2) 118 (21.3) 56 (30.9) 221 (21.2) 16.926 <0.001
dClinics 262 (84.8) 435 (78.7) 125 (69.1) 822 (78.8)
Knowledge about TB transmission
(mean  SD)
1.6  0.6 8.8  3.1 4.0  3.7 5.8  4.3 755.582 <0.001
Knowledge about TB treatment duration
(continued on next page)
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Table 5 (continued )
Variables Profile of patient c2 test or
F test
p
TB, n Z 309 HIV, n Z 553 TB_HIV,
n Z 181
Total,
n Z 1043
dInsufficient 107 (34.6) 506 (91.5) 61 (33.7) 674 (64.6) 372.042 <0.001
dGood 202 (65.4) 47 (8.5) 120 (66.3) 369 (35.4)
Knowledge about side effects of
anti-TB treatment (mean  SD)
2.4  1.6 1.1  2.2 2.7  2.0 1.8  2.1 61.168 <0.001
Other aspects about TB knowledge
(mean  SD)
3.9  1.1 6.8  1.1 4.8  1.9 5.6  1.8 588.443 <0.001
Total TB knowledge (mean  SD) 16.0  4.2 24.1  5.3 19.6  7.4 20.9  6.5 225.905 <0.001
Attitude towards TB/HIV patient
(mean  SD)
14.0  1.8 9.4  4.2 12.9  3.1 11.4  4.0 195.040 <0.001
Past history of TB or HIV (mean  SD) 1.1  0.9 0.6  0.9 1.2  1.0 0.9  0.9 38.095 <0.001
Stigma (mean  SD) 9.4  2.5 6.3  1.9 8.3  2.6 7.6  2.6 200.675 <0.001
Discrimination and isolation (mean  SD) 4.2  2.1 3.8  1.6 3.3  2.0 3.8  1.9 13.244 <0.001
Awareness to transmit disease 7.9  3.3 8.6  4.0 7.9  3.4 8.3  3.7 4.016 0.018
Psychosocial consequences of
disease (mean  SD)
9.8  2.2 9.4  1.4 10.4  2.0 9.7  1.8 24.177 <0.001
Medication adherence (mean  SD) 6.3  1.6 6.3  1.6 6.0  1.8 6.3  1.6 2.659 0.071
Alcohol status
dYes 93 (30.1) 103 (18.6) 70 (38.7) 266 (25.5) 33.726 <0.001
Smoking status
dYes 88 (28.5) 22 (4.0) 44 (24.3) 154 (14.8) 110.406 <0.001
Prisoner status
dNever been prisoner 293 (94.8) 543 (98.2) 169 (93.4) 1005 (96.4) 11.976 0.003
dAt least one time 16 (5.2) 10 (1.8) 12 (6.6) 38 (3.6)
Notion known about viral hepatitis B and C
dYes 80 (25.9) 58 (10.5) 29 (16.0) 167 (16.0) 34.967 <0.001
Sexual transmissible infections (STIs)
dNever had STIs 137 (44.3) 229 (41.4) 60 (33.1) 426 (40.8) 6.069 0.048
dAt least a once time been STIs 172 (55.7) 324 (58.6) 121 (66.9) 617 (59.2)
Illegal drug use (IDU)
dAt least a once 38 (12.3) 27 (4.9) 11 (6.1) 76 (7.3) 16.609 <0.001
dNever used drug 271 (87.7) 526 (95.1) 170 (93.9) 967 (92.7)
Diabetes status
dNo 201 (65.0) 479 (86.6) 142 (78.5) 822 (78.8) 65.560 <0.001
dYes 10 (3.2) 13 (2.4) 11 (6.1) 34 (3.3)
dUnknown 98 (31.7) 61 (11.0) 28 (15.5) 187 (17.9)
Past or present history of cardiovascular
disease
dYes 16 (5.2) 89 (16.1) 22 (12.2) 127 (12.2) 22.089 <0.001
Past or present history of arterial
hypertension
dYes 21 (6.8) 115 (20.8) 27 (14.9) 163 (15.6) 29.549 <0.001
Past or present history of pulmonary
asthma
dYes 6 (1.9) 8 (1.4) 9 (5.0) 23 (2.2) 8.002 0.018
dNumber of persons sleeping in the
household
2.8  2.2 2.4  1.4 2.4  2.0 2.7  1.8 24.177 <0.001
SSD Z standard deviation.
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This cross-sectional study was conducted via TB and HIV
clinics using health centers and NGOs of two main regions
(Centre and Hauts-Bassins) in Burkina Faso (Table 5). Our
objective was to identify predictors of the medicationadherence index among TB infected, HIV infected, and TB/
HIV coinfected patients in Burkina Faso. This study
exhaustively explored a wide range of variables using face-
to-face interviews and semi-structured questions in order
to construct strong scales and indices. Nonetheless, the
present study may be criticized because it is cross-
sectional. Furthermore, some factors explored in the
Medication adherence predictors for TB and HIV 231literature were not analyzed in the present study because
the records from the TB and HIV clinics were not identical
and because they had not been systematically collected as
part of the patients’ medical records. These included
clinical forms of TB or HIV,15,16 hemoglobin level,16 plasma
viral load,15,17,18 and undernutrition.19e21 Because this
study identified many variables associated with medical
adherence, further evaluation of their interactions may be
needed in the future.
The present study found significant differences between
socioeconomic and psychosocial variables among TB infec-
ted, HIV infected, and TB/HIV coinfected patients. This was
in agreement with the findings of a South African study, in
which the authors concluded that HIV and TB cohorts had
distinct socioeconomic and psychosocial backgrounds.5
The results showed that total TB knowledge was signif-
icantly and positively correlated with medication adher-
ence in the pooled data (p Z 0.005) and in HIV patients
(p Z 0.001) at the univariate stage and in HIV patients
(pZ 0.048) at the multivariate analysis stage. This could be
explained by information received regularly by HIV patients
during group discussions, counseling, and consultations. A
study by Kalichman et al showed that the ability of patients
to understand both their disease and its treatment had a
major effect on adherence.22 According to Okanurak et al,
a patient’s knowledge level of TB and its treatment
contributed to treatment success in Bangkok.23 In Nepal,
non-adherent patients cited insufficient knowledge about
the need to take daily treatment, especially after they felt
better, as a reason affecting patient adherence to directly
observed treatment, short course (DOTS).24 Kaona et al
reported that non-compliance was associated with a lack of
knowledge of the benefits of completing a course, with
running out of drugs at home and with the TB drugs being
“too strong” to continue.25 Thompson et al stated that
improving patients’ knowledge and understanding of their
disease and its treatment, either via nursing staff or via
community-led pharmacies, had a positive impact on
adherence levels.26
In addition to TB knowledge as adjusted predictor factor
for medication adherence, the present study found that
predictors for medication adherence were alcohol use,
attitude towards TB and HIV, awareness of disease trans-
mission, financial access to care, and high number of per-
sons sleeping in the household. At the univariate analysis
stage, Shin et al found low social support, substance use,
and depression to be associated with non-adherence.27
Corless et al reported that treatment failure was related
to inappropriate regimens, the unavailability of drugs, or
lack of access to health care.20 Sabate´ suggested that
treatment adherence was also affected by beliefs about the
origins, transmission, and treatment of TB and HIV, which
often resulted in the stigmatization of those affected.2
Several questionnaires on behavior have identified psy-
chological determinants that seem to be factors associated
with a predisposition towards non-adherence.18 Moreover,
in a multivariable analysis, Shin et al found that low social
support was associated with non-adherence.27
In contrast to the findings of a literature review, the
present study identified other adjusted predictors such as
having ever been lost to follow-up and number of persons
sleeping in the household. For patients with TB, ever beenlost to follow-up was a predictor of good medication
adherence. Because this was a cross-sectional study and
only enrolled persons returned for treatment, there may be
a loss to follow-up bias. Another explanation is that
because they returned for treatment, they had fewer
problems with complex treatment (ARV or anti-TB). In
addition, this may be explained by the Morisky scale
questions.
The present study showed the necessity to consider
different profiles of patients inside TB and HIV control
programs. Indeed, for different patient profiles (TB, HIV,
and TB/HIV coinfection), the study identified different
predicting factors of medication adherence. These factors
should be taken into consideration when designing and
implementing projects and programs for TB and HIV.
In conclusion, this study provides information on medi-
cation adherence in TB infected, HIV infected, and TB/HIV
coinfected patients. The identified factors are important
considerations that need to be incorporated into TB and HIV
programs. Factors that have to be carefully considered in
TB and HIV programs include stigma, attitude, status of loss
to follow-up, TB knowledge, financial access to care,
alcohol use, awareness of disease transmission, number of
persons sleeping in the household. TB programs can be
tailored to address each of these concerns in order to
develop educational approaches for specific groups.28 The
factors identified in this study need to be taken into ac-
count during the sensitization, project planning, and
research stages.Conflicts of interest
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